Fast Five Quiz: Prognosis of Primary Myelofibrosis

Emmanuel C. Besa, MD


July 16, 2020

The 10 year-survival rate for patients with PMF is believed to be less than 20%. The most common causes of death in patients with PMF are infections, hemorrhage, cardiac failure, postsplenectomy mortality, and transformation into acute leukemia.

Drug therapy for PMF has historically lacked disease-modifying activity. Allogenic hematopoietic stem cell transplant (allo-HCT) is the only current treatment option for PMF with curative potential; however, only a minority of patients are eligible for this intensive therapy. Patients with intermediate or high-risk PMF who are not eligible for transplant may be entered into a clinical trial or treated with a Janus kinase (JAK) inhibitor.

Learn more about treatment options for patients with PMF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.